COMP <GO>
CYTK vs PTGX // FREE CASH FLOW YIELD
Cytokinetics Incorporated (NASDAQ) VS. Protagonist Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: CYTK 1
— PTGX 9
▲ FREE CASH FLOW YIELD LEADER: PTGX
LAST: $62.03 (-1.52%) • MKT CAP: $8.76B
fcf-yield
-6.08%
LAST: $139.37 (-3.78%) • MKT CAP: $9.37B
fcf-yield
0.60%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CYTK VS. PTGX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CYTK | PTGX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -16.70% | -18.30 | PTGX | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | -6.08% | 0.60% | -6.68 | PTGX | /fcf-yield <GO> |
| Operating Margin | -60.00% | -6.00% | -54.00 | PTGX | /operating-margins <GO> |
| Net Profit Margin | -60.00% | -5.00% | -55.00 | PTGX | /net-margins <GO> |
| Revenue Growth (YoY) | 180.00% | 0.00% | +180.00 | CYTK | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.45 | 26.00 | -25.55 | PTGX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 6/9 | -1.00 | PTGX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 46.0 | 57.7 | -11.70 | PTGX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.87 | 0.99 | -0.12 | PTGX | /macro-sensitivity <GO> |
| Forward P/E Multiple | 31.0x | 31.0x | 0.00 | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $8.76B | $9.37B | -$615.9M | PTGX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CYTK REV | PTGX REV | CYTK GROSS % | PTGX GROSS % | CYTK FCF | PTGX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $88.0M | $442.8M | — | — | -$534.8M | $56.1M |
| FY 2024 | $18.5M | $708.0M | — | — | -$399.8M | $182.8M |
| FY 2023 | $7.5M | $262.2M | — | — | -$414.7M | -$70.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CYTK // BETA 0.87
PTGX // BETA 0.99